SCHEMBL6470652

SCHEMBL6470652

CNC(=O)C1(c2nccc(C)n2)CCCCC1N

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 1/20 0.41
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 2/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 2/20 0.33
ABL1 P00519 1/20 0.32
MAPK1 P28482 2/20 0.32
ALOX15 P16050 1/20 0.32
OPRL1 P41146 1/20 0.31
TLR9 Q9NR96 2/20 0.31
TLR8 Q9NR97 2/20 0.31
TLR7 Q9NYK1 2/20 0.31
FPR2 P25090 1/20 0.31
GRM5 P41594 1/20 0.31
CDK2 P24941 1/20 0.31
POLB P06746 2/20 0.31
TSHR P16473 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6472282 0.86 KMT2A (0.38) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL6470659 0.71 HSD11B1 (0.38) SLC6A3KDM4EALDH1A1HSD17B10HPGD
SCHEMBL10766155 0.68 ALDH1A1 (0.37) ALDH1A1KMT2AABL1GRM5POLB
SCHEMBL6472499 0.65 HSD11B1 (0.32)
SCHEMBL2141684 0.65 KMT2A (0.38) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL29155747 0.65 KMT2A (0.46) KDM4EALDH1A1HSD17B10KMT2AALOX15
SCHEMBL6472289 0.63 L3MBTL1 (0.44) KDM4EALDH1A1HPGDKMT2APOLB
SCHEMBL6472296 0.62 HSD11B1 (0.44) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL27945168 0.61
SCHEMBL19668539 0.61 SMN1; SMN2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 SLC6A3 144/4885KDM4E 1190/4885ALDH1A1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.